Nonprofit · EIN 83-0731767
AVENI FOUNDATION
Tax-exempt · SANTA MONICA, CA 90403
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $192,406 | $505,722 | -$313,316 | $520,956 | $382 | $520,574 |
| December 31, 2024 | 990 | $1,148,817 | $696,537 | $452,280 | $841,340 | $7,450 | $833,890 |
| December 31, 2023 | 990 | $708,687 | $471,672 | $237,015 | $381,884 | $274 | $381,610 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $192,373
- Program service revenue
- $0
- Investment income
- $33
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $0
- Compensation of officers, directors and key employees
- $0
- Other salaries and wages
- $78,000
- Salaries, compensation and benefits (total)
- $84,961
- Professional fundraising fees
- $0
- Legal fees
- $1,315
- Accounting fees
- $7,900
- Travel
- $52
- Program services (functional)
- $405,040
- Management and general (functional)
- $100,682
Balance sheet and other
- Total assets, start of year
- $841,340
- Total assets, end of year
- $520,956
- Total liabilities, end of year
- $382
- Net assets, end of year
- $520,574
- Net assets without donor restrictions
- $520,574
- Gross receipts
- $192,406
- Employees
- 4
- Year formed
- 2018
- State of legal domicile
- WA
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| REBECCA REED | QUALITY CONTROL | 40 | $108,000 |
| ERLINDA GORDON | President Trustee or director, Officer | 30 | $0 |
| MARK MASTERS | Treasurer Trustee or director, Officer | 0.5 | $0 |
| MARCE MCKINNON | Secretary Trustee or director, Officer | 0.5 | $0 |
| LANCE OSTENDORF | VICE CHAIR Trustee or director, Officer | 0.5 | $0 |
990 for the year ended December 31, 2024: 5 people
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| REBECCA REED | QUALITY CONTROL | 40 | $111,265 |
| MARCE MCKINNON | Secretary Trustee or director, Officer | 0.5 | $5,200 |
| MARK MASTERS | Treasurer Trustee or director, Officer | 0.5 | $4,000 |
| ERLINDA GORDON | President Trustee or director, Officer | 30 | $0 |
| LANCE OSTENDORF | VICE CHAIR Trustee or director, Officer | 0.5 | $0 |
990 for the year ended December 31, 2023: 4 people
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| ERLINDA GORDON | President Trustee or director, Officer | 20 | $0 |
| MARK MASTERS | Treasurer Trustee or director, Officer | 0.5 | $0 |
| MARCE MCKINNON | Secretary Trustee or director, Officer | 0.5 | $0 |
| LANCE OSTENDORF | VICE CHAIR Trustee or director, Officer | 0.5 | $0 |
Address and contacts
- Address (IRS master file)
- 2811 WILSHIRE BLVD STE 420, SANTA MONICA, CA 90403-4810
- In care of
- % DR ERLINDA GORDON
- Principal officer (990 for 2025)
- ERLINDA GORDON, 2811 WILSHIRE BLVD SUITE 420, SANTA MONICA, CA 90403
- Signed the 990
- ERLINDA GORDON, President
- Phone
- (818) 726-3278
- Website
- WWW.AVENIFOUNDATION.ORG
- Return prepared by
- Karis Accounting Inc
California records
California keeps its own records of charities and corporations. Search them by EIN 83-0731767 or by the name AVENI FOUNDATION.
- Attorney General, Registry of Charities and Fundraisers
- Registration status and filed reports (CT-TR-1, RRF-1)
- Secretary of State, bizfile Online
- Corporation status, entity number, agent for service
- Franchise Tax Board
- Entity status letter (state tax exemption, good standing)
Mission
THE AVENI FOUNDATION IS COMMITTED TO EXPEDITING DEVELOPMENT OF GENE-TARGETED THERAPIES FOR METASTATIC CANCERS AND OTHER UNMET MEDICAL NEEDS.
Program accomplishments
- THE AVENI FOUNDATION REPORTED THE PERFORMANCE OF TWO CLINICAL STUDIES:1. Compassionate Use of Intravenous DNG64-CAR-V Tumor-Targeted Retrovector Bearing a Cytocidal Dominant Negative Cyclin G1 Inhibitor for Advanced Sarcoma, Pancreatic Cancer, Non-small Cell Lung Cancer, Breast Cancer, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma (Single Use INDs)2. Blessed: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast for an Intermediate Size Population (NCT04091295)Thirty-two patients were enrolled, 18 sarcoma, 5 pancreatic ductal adenocarcinoma, 1 non-small cell lung cancer, 3 breast carcinoma, 1 prostate cancer, 1 cholangiocarcinoma, 1 basal cell carcinoma, 1 ovarian cancer, and 1 glioblastoma. Sixteen patients were enrolled in Study 1 single patient IND, 16 patients were enrolled in Study 2. Three patients were initially enrolled in Study 2 and later enrolled in Study 1. Twenty-seven of 32 enrolled patients were treated with DNG64-CAR-V either as monotherapy or in combination with FDA approved cancer therapies. Four of the 27 patients treated with DNG64-CAR-V and FDA approved drugs were also treated with either SNK01 autologous enhanced NK cell therapy or SNK02 allogeneic enhanced NK cell therapy.Nine of 15 (60%) patients treated with DNG64-CAR-V + FDA approved drugs are alive 1-71 months from treatment initiation, 2 with breast cancer are alive in complete remission, 1 with pancreatic cancer is alive with progressive disease, 3 with sarcoma are alive with either complete response s/p surgical resection, partial response or stable disease, 1 with basal cell carcinoma is alive with partial response, 1 with ovarian cancer is alive with partial response, and 1 with glioblastoma is alive receiving first cycle of treatment. Two patients with Stage 4 pancreatic adenocarcinoma who initially failed standard chemotherapy and who were treated with DNG64-CAR-V and low dose chemo lived 8.5-9.5 months, which is similar to the median survival duration of pancreatic cancer patients receiving first line therapy. One patient with metastatic liposarcoma and one patient with metastatic leiomyosarcoma who were treated with DNG64-CAR-V and low dose chemo lived 12 months, which is similar to the median survival duration of sarcoma patients receiving first line therapy.Expenses $405,040
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 83-0731767
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2019
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H30)
- Assets (IRS master file)
- $520,956
- Income (IRS master file)
- $192,406
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | $192,406 | $505,722 | $520,956 | IRS |
| 990 | December 2024 | $1,148,817 | $696,537 | $841,340 | XML |
| 990 | December 2023 | $708,687 | $471,672 | $381,884 | XML |
| 990-EZ | December 2022 | – | – | – | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990-EZ | December 2020 | – | – | – | IRS |
| 990-EZ | December 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 83-0731767).
Questions about AVENI FOUNDATION
- What is the EIN of AVENI FOUNDATION?
- The employer identification number (EIN) of AVENI FOUNDATION is 83-0731767.
- Is AVENI FOUNDATION tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2019.
- Are donations to AVENI FOUNDATION tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does AVENI FOUNDATION file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of AVENI FOUNDATION due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did AVENI FOUNDATION last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of AVENI FOUNDATION?
- The 990 for the year ended December 31, 2025 names ERLINDA GORDON.
- Who are the officers and directors of AVENI FOUNDATION?
- The 990 for the year ended December 31, 2025 lists 5 people; 1 received compensation from the organization, the highest $108,000 (REBECCA REED, QUALITY CONTROL).
- How much revenue does AVENI FOUNDATION have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $192,406, expenses of $505,722 and total assets of $520,956 at year end.
Other nonprofits in SANTA MONICA
- MOVEMBER FOUNDATION EIN 77-0714052 · last filed 990 for 2026
- WINGS FOR LIFE USA - SPINAL CORD RESEARCH FOUNDATION INC EIN 81-4795399 · last filed 990 for 2025
- FOUNDATION FOR SPINAL RESTORATION EIN 46-1150250 · last filed 990 for 2024
- CALIFORNIA ONCOLOGY RESEARCH INSTITUTE INC EIN 42-1757010 · last filed 990 for 2024
- INSTITUTE OF REGENERATIVE AND CELLULAR MEDICINE EIN 32-0421125 · last filed 990-EZ for 2024
- INNOVATIVE IMMUNO-ONCOLOGY CONSORTIUM EIN 39-2445499 · last filed 990-EZ for 2025
- FRIENDS OF OLIVER INC EIN 88-4248830 · last filed 990-EZ for 2024
- CHIARI PROJECT EIN 47-3348212 · last filed 990-N for 2025
All nonprofits in SANTA MONICA · California · Medical research